Abstract |
In a phase I-II trial, 38 patients with acute myeloid leukemia (AML) were given single drug induction therapy with aclarubicin (ACM) according to two dosing schedules: treatment 1: 10 to 30 mg/m2/d to a maximum total dose of 300 mg/m2 or until development of unacceptable toxicity: treatment 2: 15 mg/m2/d in ten-day courses separated by ten-day intervals. Response rates were 15% with treatment 1 and 44% with treatment 2 (overall response rate 34%). Complete remission (CR) was achieved in 6 patients who had previously failed to respond to adriamycin (ADM). Toxicity was more frequent and more severe in those patients given more than 150 mg/m2 ACM per course. The main side effects were oropharyngeal mucositis and diarrhea. Three patients exhibited T wave inversion and one had an episode of auricular flutter. In a separate trial in 16 patients with AML we used cyclic chemotherapy combining ACM (20 mg/m2/d) and ARA-C (200 mg/m2/d) for seven consecutive days. Complete remission rate was 50%. Severe ventricular rhythm disorders were seen in two patients. In a phase I-II study, 19 patients with acute lymphoid leukemia (ALL) and 8 patients with non-Hodgkin lymphoma (NHL) were given ACM alone according to the regimen designated treatment 1 described above. Response rates were 11% (2/19) in ALL and 25% (2/8) in NHL. A review of the literature is presented in the discussion of the original trials reported herein.
|
Authors | D Machover, E Goldschmidt, M Benavides, J Gastiaburu, J M Vandenbulcke, M Delgado, J L Misset, G Mathe |
Journal | Pathologie-biologie
(Pathol Biol (Paris))
Vol. 35
Issue 1
Pg. 79-86
(Jan 1987)
ISSN: 0369-8114 [Print] France |
Vernacular Title | Essais thérapeutiques de l'aclarubicine dans les leucémies aiguës et les hématosarcomes antérieurement traités. |
PMID | 3550616
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Naphthacenes
- Cytarabine
- Aclarubicin
|
Topics |
- Aclarubicin
- Adolescent
- Adult
- Aged
- Antibiotics, Antineoplastic
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Cytarabine
(therapeutic use)
- Drug Evaluation
- Female
- Humans
- Leukemia, Lymphoid
(drug therapy)
- Leukemia, Myeloid, Acute
(drug therapy)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Naphthacenes
(therapeutic use)
|